Custom Retatrutide (CAS NO: 2381089-83-for Obesity and T2DM - China Suppliers and Factory Offering Innovative Solutions Manufacturers, Pricelist
Product Description
Obesity and type 2 diabetes mellitus (T2DM) are global health crises with significant morbidity and mortality. Retatrutide, a novel triple receptor agonist targeting glucagon-like peptide-1 (GLP-1), Glucose-Dependent Insulinotropic Polypeptide (GIP), and glucagon receptors, represents a groundbreaking advancement in obesity and T2DM pharmacotherapy.
Mechanism & Efficacy
Retatrutide is a novel multi-agonist peptide targeting GLP-1, GIP, and glucagon receptors, designed to enhance glucose regulation, promote weight loss, and support metabolic health. It is under active investigation in clinical and preclinical research for obesity and type 2 diabetes management.
Dosage & Research Use
Retatrutide is currently an investigational peptide in Phase 3 clinical trials and not yet FDA‑approved for clinical use. Trial protocols have explored once‑weekly subcutaneous doses ranging from 1 mg up to 12 mg, often titrated over multiple 4‑week intervals to balance efficacy and tolerability.
Frequently Asked Questions
What is Retatrutide?
Retatrutide is a novel multi-agonist peptide that acts as a triple receptor agonist targeting GLP-1, Glucose-Dependent Insulinotropic Polypeptide (GIP), and glucagon receptors.
What conditions is Retatrutide being investigated for?
It is currently under active investigation in clinical and preclinical research primarily for the management of obesity and type 2 diabetes mellitus (T2DM).
How does Retatrutide work?
By targeting three key metabolic receptors, Retatrutide is designed to enhance glucose regulation, promote significant weight loss, and provide overall support for metabolic health.
Is Retatrutide currently FDA-approved?
No, Retatrutide is currently an investigational peptide in Phase 3 clinical trials and has not yet been FDA-approved for clinical use.
What is the typical dosage explored in research?
Trial protocols have explored once-weekly subcutaneous doses of Retatrutide ranging from 1 mg up to 12 mg.
Why is the dosage of Retatrutide titrated?
The dosage is often titrated over multiple 4-week intervals during clinical trials to carefully balance its efficacy with patient tolerability.
